Participation in two phase II prophylactic HIV vaccine trials in the UK

Vaccine

Volumn 26, Issue 23, 2008, Pages 2919-2924

  Gray, Kimberly ^a,b   Legg, K ^c   Sharp, A ^a   Mackie, N ^c   Olarinde, F ^a   De Souza, C ^c   Weber, J ^c   Peters, B ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Guidelines; HIV prophylactic vaccines; Recruitment

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO;

ADULT; ALTRUISM; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MASS MEDIUM; PATIENT PARTICIPATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCREENING; UNITED KINGDOM;

ADULT; AIDS VACCINES; CLINICAL TRIALS, PHASE II AS TOPIC; DATA COLLECTION; FEMALE; GREAT BRITAIN; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; RESEARCH SUBJECTS;

EID: 43349095854     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.039     Document Type: Article

References (28)

1. UNAIDS, AIDS epidemic update: a special report on HIV/AIDS: December 2006, Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2006, http://www.unaids.org/en/HIV_data/epi2006.
2. Cohen J. Promising AIDS vaccine's failure leaves field reeling. Science 318 (2007) 28-29
3. International AIDS Vaccine Initiative (IAVI). IAVI Database of AIDS Vaccines in Human Trials. IAVI, February 22; 2008, http://www.iavireport.org/trialsdb/searchresults4.asp?list=vaccine&t s=.&vt=.
4. Esparza J., Osmanov S., Pattou-Markovic C., Toure C., Chang M.L., and Nixon S. Past, present and future of HIV vaccine trials in developing countries. Vaccine 20 (2002) 1897-1898
5. Klausner R.D., Fauci A.S., Corey L., Nabel G.J., Gayle H., Berkley S., et al. The need for a global HIV vaccine enterprise. Science 300 (2003) 2036-2039
6. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from WHO/UNAIDS/IAVI technical consultation on phase IIB test of concept trials (TOC) as a novel strategy for evaluation of preventative HIV vaccines. AIDS 21 (2006) 539-546
7. de Bruyn G., Hudgens M.G., Sullivan P.S., and Duerr A.C. Participant retention in clinical trials of candidate HIV vaccines. J Acq Immun Def Synd 39 (2005) 499-501
8. Jenkins R.A., Chinaworapong S., Morgan P.A., Ruangyuttikarn C., Sontirat A., Chiu J., et al. Motivation, recruitment, and screening of volunteers for a phase I/II HIV preventive vaccine trial in Thailand. J Acq Immun Def Synd Hum Retrovirol 18 (1998) 171-177
9. Thapinta D., Jenkins R.A., Celentano D.D., Nitayaphan S., Buapunth P., Triampon A., et al. Evaluation of behavioural and social issues among Thai HIV vaccine trial volunteers. J Acq Immun Def Synd Hum Retrovirol 20 (1999) 308-314
10. Thapinta D., Jenkins R.A., Morgan P.A., Chiu J., Boenim W., Bussaratid V., et al. Recruiting volunteers for a multi-site phase I/II HIV preventive vaccine trial in Thailand. J Acq Immun Def Synd 30 (2002) 503-513
11. Crumbo C.L., Rybczyk G.K., and Wagner L.J. Characteristics of volunteer participants in phase I HIV vaccine trials. J Assoc Nurses AIDS Care 8 (1997) 59-65
12. Buchbinder S.P., Metch B., Holte S., Scheer S., Coletti A., and Vittinghoff E. Determinants of enrolment in a preventative HIV vaccine trial. J Acq Immun Def Synd 36 (2004) 604-612
13. Johnson M.O. Belief of vaccine receipt in HIV vaccine trials: further cautions. J Acq Immun Def Synd 21 (1999) 413-416
14. Mills E., Cooper C., Guyatt G., Gilchrist A., Rachlis B., Sulway C., et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 18 (2004) 2235-2242
15. Peters B.S., Jaoko W., Vardas E., Panayotakopoulos G., Fast P., Schmidt C., et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25 (2007) 2120-2127
16. UK Collaborative Group for HIV and STI Surveillance London. Mapping the issues. HIV and other sexually transmitted infections in the United Kingdom. London: Health Protection Agency Centre for Infections; 2005. http://www.hpa.org.uk/publications/2005/hiv_sti_2005/default.htm.
17. Brooks R.A., Newman P.A., Duan N., and Ortiz D.J. HIV vaccine trial preparedness among Spanish-speaking Latinos in the US. AIDS Care 19 (2007) 52-58
18. Newman P.A., Duan N., Rudy E.T., and Anton P.A. Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?. AIDS Patient Care STDS 18 (2004) 691-701
19. Newman P.A., Duan N., Roberts K.J., Seiden D., Rudy E.T., Swendeman D., et al. HIV Vaccine trial participation among ethnic minority communities: barriers, motivators, and implications for recruitment. JAIDS 41 (2006) 210-217
20. Djomand G., Katzman J., di Tommaso D., Hudgens M.G., Counts G.W., Koblin B.A., et al. Enrolment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988-2002. Public Health Rep 120 (2005) 543-548
21. Sengupta S., Strauss R.P., DeVellis R., Quinn S.C., DeVellis B., and Ware W.B. Factors affecting African-American participation in AIDS research. J Acq Immun Def Synd 24 (2000) 275-284
22. Priddy F.H., Cheng A.C., Salazar L.F., and Frew P.M. Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. Int J STD AIDS 17 (2006) 99-102
23. Sheon A.R., Wagner L., McElrath M.J., Keefer M.C., Zimmerman E., Israel H., et al. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J Acq Immun Def Synd Hum Retrovirol 19 (1998) 519-526
24. Allen M., Israel H., Rybczyk K., Pugliese M.A., Loughran K., Wagner L., et al. Trial-related discrimination in HIV vaccine clinical trials. AIDS Res Hum Retrov 17 (2001) 667-674
25. Colfax G., Buchbinder S., Vamshidar G., Celum C., McKirnan D., Neidig J., et al. Motivations for participating in an HIV vaccine efficacy trial. J Acq Immun Def Synd 39 (2005) 359-364
26. Newman P.A., Daley A., Halpenny B., and Loutfy M. Community heroes or "high risk" pariahs? Reasons for declining to enroll in an HIV vaccine trial. Vaccine 26 (2008) 1091-1097
27. Chesney M.A., Lurie P., and Coates T.J. Strategies for addressing the social and behavioral challenges of prophylactic HIV vaccine trials. J Acq Immun Def Synd Hum Retrovirol 9 (1995) 30-35
28. Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2 (2005) e25